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Abstract
Background: NANOG is a homeodomain-containing transcription factor
which forms one of the hubs in the pluripotency network and plays a key
role in the reprogramming of somatic cells and epiblast stem cells to naïve
pluripotency. Studies have found that NANOG has many interacting
partners and some of these were shown to play a role in its ability to
mediate reprogramming. In this study, we set out to analyse the effect of
NANOG interactors on the reprogramming process.
Methods: Epiblast stem cells and somatic cells were reprogrammed to
naïve pluripotency using MEK/ERK inhibitor PD0325901, GSK3β inhibitor
CHIR99021 and Leukaemia Inhibitory Factor (together termed 2i Plus LIF).
Zmym2 was knocked out using the CRISPR/Cas9 system or overexpressed
using the PiggyBac system. Reprogramming was quantified after ZMYM2
deletion or overexpression, in diverse reprogramming systems. In addition,
embryonic stem cell self renewal was quantified in differentiation assays
after ZMYM2 removal or overexpression.
Results: In this work, we identified ZMYM2/ZFP198, which physically
associates with NANOG as a key negative regulator of NANOG-mediated
reprogramming of both epiblast stem cells and somatic cells. In addition,
ZMYM2 impairs the self renewal of embryonic stem cells and its
overexpression promotes differentiation.
Conclusions: We propose that ZMYM2 curtails NANOG’s actions during
the reprogramming of both somatic cells and epiblast stem cells and
impedes embryonic stem cell self renewal, promoting differentiation.
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Introduction
Reprogramming is the process whereby a somatic cell is reverted
back to a pluripotent state. Pluripotent cells possess the ability
both to self-renew and to differentiate into cells from any of the
three germ layers of the adult organism. Reprogramming can
be carried out by overexpressing only four factors in somatic
cells: Oct4, Klf4, Sox2 and cMyc1. Together, these factors reset
the transcriptional and epigenetic state of the cell to those of
a pluripotent cell. Much work has been carried out on factors
which can execute or promote this transition. These include many
members of the pluripotency-associated transcription factor
network2–7. Nanog is a homeodomain-containing transcription
factor which constitutes one of these key factors.
Nanog was first discovered for its ability to promote embryonic stem cell (ESC) self-renewal in the absence of LIF and for
its association with the pluripotent state as opposed to somatic
identities8,9. Nanog is also essential for the establishment of the
pluripotent naïve epiblast10. Thus, Nanog plays a central role in
the promotion of the pluripotent state, both in vitro and in vivo.
As a key hub of the pluripotency network, studies have been carried out aiming at understanding Nanog’s mode of action. One
approach was to define its interactome, which led to the identification of multiple interactors3,11,12. Some of these are chromatin
modifiers that were shown to augment the ability of Nanog to
mediate reprogramming. These include the NuRD complex13
and the TET family proteins11. Importantly, we still do not know
if most of the identified interactors play a role, either positive
or negative, in the mechanism of action of Nanog. In order
to address this, we set out to analyse the effect of additional
NANOG interactors on Nanog-mediated reprogramming. This
work enabled us to identify ZMYM2/ZFP198, which physically
associates with NANOG3,11,12,14, as a key protein impairing
Nanog’s activity in both reprogramming and the self-renewal of
naïve pluripotent stem cells.

Methods
Cell culture

(Invitrogen, 25030024), 1X Pen/Strep, 0.1 mM 2-mercaptoethanol
(Invitrogen 31350-010).
Epiblast stem cells (EpiSCs) were cultured in N2B27-containing medium supplemented with 12.5 ng/mL FGF2 (WT/MRC
SCI, University of Cambridge) and 20 ng/mL Activin A (WT/
MRC SCI, University of Cambridge). They were grown on
dishes which had been coated with 10 μg/mL Human recombinant fibronectin (Millipore FC010) in PBS for 30 min at
room temperature.
Neural stem cells (NSCs) were cultured in DMEM/F12 (Life
Technologies, 11330-057) containing 27.4mM glucose, 1x NEAA
(PAA, M11-003), 1X Pen/Strep (PAA, P11010), 4mM HEPES
(Life Technologies, 15630-049), 0.011% Bovine serum albumin,
1X N2 (WT/MRC SCI, University of Cambridge), 1X B27
(Life Technologies, 17504-044), 0.1 mM 2-mercaptoethanol
(Invitrogen 31350-010), 10 ng/mL of epidermal growth factor
(EGF; Peprotech, 315-09) and 20 ng/mL fibroblast growth
factor 2 (FGF2; WT/MRC SCI, University of Cambridge). They
were cultured on plastic dishes which had been coated for at least
3 h with 10 μg/mL laminin (Sigma, L2020) in PBS and washed
once in PBS.

Cell lines
Oct4 reporter EpiSCs and NSCs were used as previously detailed
and contained an Oct4-GFP-IRES-puro reporter transgene in
which enhanced green fluorescent protein (eGFP) is expressed
under the control of Oct4 (Pou5f1) regulatory elements15,16.
Nanog-GFP-IRES-puro reporter NSCs were also used as previously generated and these contained GFP inserted heterozygously
into the AUG start codon of one endogenous Nanog allele11,17.
Nanog-/- pre-iPSCs had been previously generated in the lab
by the retroviral transduction of Nanog-/- NSCs isolated from
E12.5 forebrain with Oct4, Klf4 and cMyc10 E14tg2a ESCs were
used for all self-renewal assays18.

Mouse ESCs, iPS cells and pre-iPS cells were cultured in
Glasgow Minimum Essential Medium (GMEM; Sigma, G5154)
containing 10% foetal calf serum (FCS; Life Technologies,
10091-148), 1x non-essential amino acids solution (NEAA; PAA,
M11-003), 1 mM sodium pyruvate (PAA, S11-003), 0.1 mM
2-mercaptoethanol (Invitrogen 31350-010), 2mM L-glutamine
(Invitrogen, 25030024), 1x Pen/Strep (PAA, P11010) and 20 ng/mL
LIF (Department of Biochemistry, University of Cambridge).
This medium will hereafter be referred to as Serum Plus LIF.
These cells were grown on plastic dishes (Iwaki/Corning,
10578911) which had treated with 0.1% gelatin for 10 min.
Fibroblasts were cultured in GMEM (Sigma, G5154) containing
10% FCS (Life Technologies, 10091-148) on gelatin-coated
dishes.

siRNA transfection
FlexiTube siRNA solutions (Qiagen) were used to knock down
expression of the following genes: Zmym2 (GS76007), Zfp281
(GS226442) and Nr0b1 (GS11614). All Star negative control
siRNA was also used (1027281). Transfection was carried out
with Lipofectamaine RNAi Max (Life Technologies, 13778030).
Medium was changed to medium containing MEK/ERK
inhibitor PD0325901, GSK3β inhibitor CHIR99021 (WT/MRC
SCI, University of Cambridge) and Leukaemia Inhibitory Factor (Department of Biochemistry, University of Cambridge)
(together termed 2i Plus LIF)19 with Penicillin/Streptomycin
24 h after transfection and the cells were allowed to reprogram
for 12 days. Green colonies, resulting from the expression of
a Oct4-GFP reporter11,13,20, were monitored using a Leica epifluorescent DMI4000 microscope at 488nm as a readout of
reprogramming efficiency.

N2B27-containing medium was made up as follows: 50%
neurobasal (Life Technologies, 21103-049), 50% Dulbecco’s
Modified Eagle Medium (DMEM)/F12 (Life Technologies,
11330-057), 1X N2 (WT/MRC SCI, University of Cambridge),
1X B27 (Life Technologies, 17504-044), 2mM L-glutamine

Measurement of pluripotency-associated gene expression
by qPCR
Total RNA was extracted from cells using an RNeasy mini kit
(Qiagen, 74106), with DNAse treatment (Qiagen, 79254). cDNA
synthesis was performed using the Superscript III kit (Life
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Technologies, 11752-250) in accordance with the manufacturer’s protocol. RT-qPCR was carried out in microAmp qPCR
plates (Life Technologies, 434690) on a StepOne Plus Real-Time
PCR machine (Applied Biosystems) using TaqMan Fast Universal MasterMix (Applied Biosystems, 4352042) and expression
levels were calculated by ΔCt to Gapdh. Mean expression
levels were determined by averaging triplicate wells. TaqMan
amplification was performed as follows: 2 min at 50 °C, 20 sec
at 95 °C, (1 sec at 95 °C, 20 sec at 60 °C) x 40. Probes used are
presented in Table 1.

Reprogramming neural stem cells and mouse embryonic
fibroblasts
Retroviral reprogramming vectors (pMXs-Oct4 (13366), pMXsKlf4 (13370), pMXs-Sox2 (13367) and pMXs-cMyc (13375))
were obtained from the Addgene repository. PLAT-E cells
were transfected with these using FuGene (Promega E2311).
The medium containing retroviral particles was collected from
the PLAT-E cells and filtered through a 0.45 μm filter. Neural
stem cells (NSCs) were transduced with retroviral (r) Oct4,
cMyc and Klf4 whereas MEFs were transduced with these and
rSox2. 4μg/ml polybrene (Sigma Aldrich, TR-1003) was added
for transduction.
24 h after transduction, the virus-containing medium was
aspirated from the NSCs or MEFs and replaced with the cells’
respective media. Four days after transduction, the medium
was replaced with Serum-containing medium supplemented
with Leukaemia Inhibitory Factor21 (Serum Plus LIF). The cells

Table 1. Probes used for qPCR.
Probe

Applied Biosystems ID

Klf4

Mm00516104_m1

Klf2

Mm01244979_g1

Rex1

Mm03053975_g1

Nr0b1

Mm00431729_m1

Oct4

Mm00658129_gH
Mm00442411_m1

Nanog

Mm02384862_g1

Gapdh

Mm99999915_g1

Cells were then stably transfected with PiggyBac (PB) Nanog
transgenes, selected and subjected to transient transfection with
siRNA before reprogramming in 2i Plus LIF. Oct4- or NanogGFP+ colonies were counted 12 days later (see cell line section
for details).

Zmym2 overexpression
Overexpression vectors were generated using Gateway cloning (Invitrogen) and PiggyBac vectors. Cells were transfected
using Lipofectamine 2000 (ThermoFisher Scientific 11668019)
and selected for 14 days with either hygromycin or blasticidin
(WT/MRC SCI, University of Cambridge).
CRISPR/Cas9 generation of Zmym2-/- EpiSC and NSC
cells
A double-stranded break was induced 108 amino acids after the
start codon of Zmym2, inducing frameshift mutations in both
alleles. Pools of clones were screened by T7 assay22, which
involves the annealing of PCR products from the edited locus to
PCR products from the WT locus. These double stranded fragments are then digested with T7 endonuclease, which cuts the
imperfectly annealed strands. These cut products can then be
visualised using agarose gel electrophoresis. Single transfected
cells were then sorted and analysed for ZMYM2 knockout by
Western Blotting (see Table 2 for antibodies used). Clones
were selected which had no intact Zmym2 alleles and were
stably transfected with Nanog or Zmym2 transgenes or both, or
their corresponding empty vector transgenes.
Antibodies
Self-renewal assay for ESCs. Zmym2 was stably overexpressed
in ESCs or knocked out by CRISPR/Cas9 as detailed above.
These cells were plated alongside Empty Vector (EV) controls
in Serum-containing medium with or without LIF for 6 days.
Alkaline-phosphatase staining (Sigma, 86R-1KT) was carried
out and colonies were scored by both morphology and alkaline
phosphatase staining.

Zmym2 Mm00813221_m1
Esrrb

slowly became more proliferative and acquired pre-iPS cell-like
morphology. If the pre-iPS were being reprogrammed in the same
well, the medium was switched to medium containing MEK/
ERK inhibitor PD0325901, GSK3β inhibitor CHIR99021 (WT/
MRC SCI, University of Cambridge) and Leukaemia Inhibitory
Factor (Department of Biochemistry, University of Cambridge)
(together termed 2i Plus LIF)19 4 days after the application of
Serum Plus LIF (8 days after retroviral transduction).

Table 2. Antibodies used for western blots.
Target

Species Clonality Concentration Dilution Cat no

Supplier

alpha tubulin

mouse

Mono

1 mg/mL

1:5000

ab7291

Abcam

NANOG

rat

Mono

500 μg/mL

1:100

eBio MLC51 eBiosciences

OCT4 C10

mouse

Mono

200 μg/mL

1:500

sc-5279

Santa Cruz

ZMYM2

rabbit

Poly

400 μg/mL

1:440

ab30783

Abcam
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Transcriptome analysis
mRNA was extracted with a RNeasy kit (Qiagen, 74106), with
DNAse treatment (Qiagen, 79254). It was quantified using Agilent Bioanalyzer Nano Chips (Agilent Technologies). Depletion of ribosomal RNA was performed on 2-5 μg of total RNA
using the Ribo-Zero rRNA Removal Kit (Illumina) and libraries
were produced from 10-100ng of ribosomal-depleted RNA
using NextFlex Rapid Directional RNA-seq Kit (5138-07;
Bioo Scientific), a Biorad C1000 thermocycler, and standard
Illumina primers. Cycling conditions were as follows: 30 min
at 37°C, 2 min at 98°C, (30 sec at 98°C, 30 sec at 65°C, 60 sec
at 72°C) x 12, 4 min at 72°C. Libraries were pooled in equimolar quantities and sequenced on the HiSeq4000 platform
(Illumina), using V4 chemistry.
RNA-seq reads were adaptor-trimmed with TrimGalore (version 0.3.7) and mapped to the mouse reference genome
(GRCm38/mm10) with TopHat2 (version 2.2.3). Strand-specific
read counts were obtained with featureCounts (version 1.4.5).
Transcript counts were normalised, and the statistical significance
of differential expression between samples was assessed using
the R Bioconductor DESeq2 (version 1.4.5) package. Transcript
counts normalized by DESeq2 size factors were subsequently
normalized by their length.

Blastocyst injection and animal husbandry
Chimeras were generated from mouse strain 129 (agouti coat
color) iPSCs by standard microinjection methodology at the
Wellcome Trust/MRC Cambridge Stem Cell Institute. Briefly,
host blastocysts of strain C57BL/6 (black coat colour) were
injected at E4.5, followed by gestation in pseudo-pregnant recipient females23. These females were 6–10 weeks old and 25–30g.
The resulting chimeras were then bred with WT mice and the
pups analysed by coat colour for contribution of the iPS-derived
cells. The use of animals in this project was approved by
the Animal Welfare and Ethical Review Body for the University
of Cambridge (Procedure Project Licenses P76777883 and
80/2597). Mice were housed in individual ventilated cages
with up to 5 animals per cage. Stud males were individually
caged and females were housed in groups, with wood chips
and mouse bedding plugs on the cage floor. The mouse facility
was a barrier facility with 10 hours darkness and 14 hours light
per day. The temperature was maintained at 22 °C. Food and
water were provided ad libitum. Cages contained environmental enrichment for the mice, including wooden blocks and
perspex houses. All animals were checked on a daily basis
by trained animal house staff, but there are no welfare issues

expected from the embryo transfer procedure, which is performed
routinely by the dedicated transgenic facility manager. Every
effort was made to reduce the numbers of animals used and the
stress or discomfort caused to animals in this study. The final assay
result is coat colour of the pups, and did not involve any invasive or stressful procedures. Further details regarding the mice
used are presented in Table 3.

Results
Zmym2 impairs Nanog -mediated reprogramming in EpiSCs
In this study, we aimed to characterise potential regulators of
Nanog’s activity during reprogramming. We compared NANOG
interactomes3,11,12 and selected ZMYM2 and NR0B1 as candidates of interest due to these being high confidence interactors.
ZFP281 was selected as a control, as knocking it down had been
previously demonstrated to increase Nanog-mediated reprogramming efficiency24. In order to address whether these factors
impact Nanog-induced reprogramming, Nanog-overexpressing
EpiSCs, which reprogram at low efficiency10,20, were transiently
transfected with siRNA against the target genes of interest
(Figure 1A). The medium was then swapped to medium containing the MEK/ERK inhibitor PD0325901 and the GSK3β inhibitor CHIR9902119. This medium will hereafter be referred to
as (2i) plus LIF medium (2i Plus LIF). This medium promotes
reprogramming19. These cells express enhanced green fluorescent
protein (eGFP), under the control of Oct4 (Pou5f1) regulatory
elements, making the cells GFP+ when fully reprogrammed
to naïve pluripotency15,16. As a readout of reprogramming
efficiency, Oct4-GFP+ colonies were counted 12 days after
the application of 2i Plus LIF.
Nr0b1 knockdown (KD) did not alter reprogramming efficiency.
Zfp281KD increased Nanog mediated reprogramming efficiency,
consistent with a previous report24. Interestingly, reprogramming
efficiency was robustly increased by Zmym2KD (Figure 1A).
Zmym2 transcript and protein levels were reduced by all four
siRNAs by qPCR and by Western blot (Figure 1B and 1C
respectively), 48h after transfection. This contrasts with the
action of many other NANOG interactors as activators of
reprogramming11,13 and suggests that Zmym2 impedes Nanogmediated reprogramming. The iPSCs generated after Zmym2KD
were characterised and had gene expression profiles consistent
with the acquisition of naive pluripotency (Figure 1D) and
upon injection into C57Bl6 mouse host blastocysts, chimerae
were produced (Figure 1E). Zmym2KD iPSCs also exhibited
germline competence (Figure 1F). This indicates faithful iPSC
reprogramming following Zmym2KD.

Table 3. Details of mice used for chimera contribution assay. Zmym2 KD or OE iPSCs were injected into E4.5 C57Bl6 host
blastocysts. The resulting embryos were implanted into pseudopregnant females and the pups analysed for iPS contribution by coat
colour. M:male, F:female, GLT: germline transmission.
Contribution
Date

Clone
name

No. of
Strain
Females

No. of
No.
No.
No.
No.
No. No. of
M F high medium Low GLT
embryos injected transferred recipients pregnant born chimeras

13/05/2013 Zmym2 12
KD

C57Bl6 74

70

70

5x25

2

17

5

3

2 0

5

0

Yes

14/06/2013 Zmym2 9
OE

C57Bl6 21

20

20

2x25

1

2

0

0

0 0

0

0

N/A
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Figure 1. Zmym2 is a repressor of Nanog-mediated epiblast stem cell (EpiSC) reprogramming. a, 2000 EpiSCs were transiently transfected
with siRNA against the indicated targets and reprogrammed by Nanog overexpression in 2i Plus LIF. Oct4-GFP+ colonies were scored on
day 12. Data represent the mean number of Oct4-GFP+ colonies from two replicates +/- SEM. Example colonies are shown in the inset panel.
b, RT-qPCR analysis of EpiSC lines 48h after Zmym2KD. Data are the mean normalized expression level from 3 technical replicates +/- SD.
c, Western Blot of EpiSC lines 48h after Zmym2KD with alpha tubulin shown as a loading control. d, Gene expression analysis of the parent
EpiSCs and resulting iPSCs by qPCR. Data are the mean normalised expression levels from 3 technical replicates +/- SD. e, iPSCs which
emerged from Zmym2KD EpiSCs were injected into C57Bl6 blastocysts to generate chimeras, which can be seen from their coat colour
(brown fur conferred by iPSC contribution). f, Germline transmission of the iPSCs (brown pup from iPSCs shown with its chimera mother and
black father). g, Western Blot of lines of empty vector (EV) and NANOG-overexpressing (Nanog) EpiSCs with alpha tubulin shown as a loading
control. h, GFP+ colony count of EV- and Nanog-overexpressing EpiSCs when reprogrammed in the presence of siRNA against Zmym2 or
control siRNA. Data represent the mean +/- SEM of two independent experiments.
Page 6 of 18
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Given that these EpiSCs overexpressed Nanog to promote reprogramming, we then investigated whether Zmym2KD is sufficient
to reprogram EpiSCs in the absence of any transgenic reprogramming factors. In order to address this, EpiSCs overexpressing Nanog or a corresponding empty vector (EV) transgene
(Figure 1G) were transfected with siRNA against Zmym2 and
transferred to reprogramming conditions. Zmym2KD had a pronounced positive effect on Nanog-induced reprogramming but a
minimal effect on the reprogramming of EV EpiSCs (Figure 1H).
Therefore, Zmym2KD relies on the exogenous expression of Nanog
in order to robustly enhance reprogramming.

Zmym2 impairs Nanog -mediated somatic cell
reprogramming
All experiments described so far had been carried out in EpiSCs.
We used reprogramming intermediates generated from neural
stem cells (NSCs) through retroviral expression of Oct4, Klf4 and
cMyc, to address whether Zmym2 might also inhibit Nanog-induced
reprogramming in a somatic cell context. These cells were stably
transfected with a PiggyBac (PB) Nanog transgene and subjected
to transient transfection with either control or Zmym2 siRNA. In
keeping with the results obtained in EpiSCs, Zmym2KD increased
somatic cell reprogramming more than two-fold (Figure 2A).
To ascertain whether Zmym2KD could reprogram somatic cells
in the absence of Nanog, the same experiment was carried out in
Nanog-/- somatic cells10. These were stably transfected with a rescue Nanog transgene or a corresponding EV transgene, and reprogrammed after control KD or Zmym2KD. As seen in Figure 2B,
Zmym2KD also enhanced Nanog-mediated reprogramming in
neural stem cell derived reprogramming intermediates. Zmym2KD
was not sufficient to overcome the requirement for Nanog in
somatic cell reprogramming, though we confirmed that it enhances
Nanog-mediated reprogramming in this context.
As Zmym2KD increases Nanog-mediated reprogramming efficiency, we decided to carry out the converse experiment and
investigate whether Zmym2 overexpression could impair reprogramming. Four lines of EpiSCs were generated which stably
overexpressed either Nanog, Zmym2, or both (Figure 2C),
and these were induced to reprogram by transfer to 2i Plus LIF
medium. As expected, Nanog overexpression resulted in efficient
EpiSC reprogramming while Zmym2 overexpression alone had
no reprogramming activity (Figure 2D). However, when Zmym2
overexpression was combined with Nanog overexpression, it
reduced reprogramming efficiency 8-fold relative to Nanog alone
(Figure 2D). To test this result in an independent cell system
mouse embryonic fibroblast (MEF)-derived reprogramming
intermediates expressing retroviral Oct4, Klf4, cMyc and Sox2
and a Nanog transgene were transfected with either Empty
Vector (EV) or a Zmym2 expression cassette (Figure 2E).
Nanog alone led to highly efficient complete reprogramming
(Figure 2F, G, H) whereas the addition of Zmym2 completely
prevented reprogramming.
In order to investigate the effect of Zmym2 loss in reprogramming, Zmym2-/- EpiSCs were generated by CRISPR/Cas9-mediated
mutagenesis (Figure 3A). WT and Zmym2-/- EpiSCs were then
stably transfected with Nanog or Zmym2 or both (Figure 3A)

and allowed to reprogram. Similar to previous results, Zmym2
overexpression decreased Nanog-mediated reprogramming in
wild type cells (Figure 3B). In agreement with KD experiments,
Zmym2 knockout increased Nanog-induced reprogramming
by about 4-fold (Figure 3B). This effect was rescued by the
addition of transgenic Zmym2 (Figure 3B). WT and Zmym2-/iPSCs were indistinguishable by gene expression analysis
of pluripotency-associated markers (Figure 3C).
To verify this result in an independent cell system, WT or
Zmym2-/- NSCs were also generated by CRISPR/Cas9-mediated
mutagenesis (Figure 3D). They were then retrovirally transduced
with Oct4, Klf4 and cMyc and allowed to reprogram. As in EpiSCs,
Zmym2-/- NSCs reprogrammed with much higher efficiency than
their WT counterparts (Figure 3E, F). Both WT and Zmym2-/iPSCs had gene expression profiles similar to those of control
ESCs, demonstrating complete reprogramming (Figure 3G).
Both WT and Zmym2-/- NSC lines were then stably transfected with Nanog, Zmym2, or both, to create a rescue system
for reprogramming (Figure 3D). Again, Zmym2 knockout increased
Nanog-induced reprogramming by 3-fold (Figure 3H), whereas
its overexpression eliminated the enhancement of reprogramming
by Nanog (Figure 3H).

Zmym2 reduces ESC self-renewal
Zfp281 is known to enable Nanog autorepression24 so we tested
whether Zmym2 levels had any effect on Nanog transcript levels.
Neither KD nor overexpression lines had any change in Nanog
transcript or protein levels (Figure 1B, 1C, Figure 2C,
Figure 3C, 3G), suggesting that Zmym2 does not act through the
regulation of Nanog expression.
Nanog was first discovered for its role in the self-renewal of
ESCs8,9. As ZMYM2 is a NANOG interactor, we hypothesised
that it might also inhibit Nanog’s self-renewal-promoting
capacity. In order to address this, Zmym2 was stably transfected into ESCs. These cells were plated alongside EV controls
(Figure 4A) in Serum-containing medium with LIF for 6
days, to maintain pluripotency in some cells while allowing
others to differentiate. Alkaline-phosphatase staining was carried
out and colonies were scored. Zmym2-overexpressing ESCs
exhibited greater spontaneous differentiation than control ESCs
(Figure 4B, C).
In order to investigate whether Zmym2KO impedes ESC differentiation, both Zmym2 alleles were knocked out using the
CRISPR/Cas9 system as previously described. ZMYM2-/- cells and
FLAG-tagged Zmym2 rescue cells were generated (Figure 4D).
These lines were plated alongside the parental WT ESC line in
the absence of LIF for 6 days, alkaline phosphatase stained and
colonies were scored by morphology. Zmym2KO increased
the proportion of undifferentiated colonies (Figure 4E). This was
rescued by transgenic Zmym2 expression. This is in agreement
with a recently published Cas9 ESC differentiation screen which
demonstrated that Zmym2KO ESCs resist differentiation25.
To address the global effects of Zmym2 loss on the transcriptome, mRNA from Zmym2 KO, WT and overexpressing ESCs
(Figure 5A, B) were subjected to mRNA-Seq after culture in
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Figure 2. Zmym2 inhibits somatic cell reprogramming in a Nanog-dependent manner. a, Neural stem cells (NSCs) were reprogrammed
with retroviral Oct4, Klf4 and cMyc and with constitutive transgenic Nanog expression in 2i Plus LIF in the presence of Zmym2 or control
siRNA. Colony count per 75,000 plates NSCs. Average of three independent experiments. **** p<0.0005 by Student’s T-test. b, Average
GFP+ colony count per 10,000 Nanog-/- pre-iPSCs reprogrammed in the presence of Zmym2 or control KD, two replicates +/-SEM c, Gene
expression analysis of EpiSC lines stably overexpressing Nanog, Zmym2, or both by RT-qPCR. d, Average GFP+ colony count on D12 after
2i Plus LIF application per 25,000 plated EpiSCs, three replicates. e, Gene expression analysis by qPCR of MEF-derived pre-iPSCs stably
overexpressing Nanog+EV or Nanog+Zmym2, with ESC control. f, Fluorescence and brightfield images of Oct4-GFP+ colonies on D12 g,
Average GFP+ colony count on D12 per 50,000 plates pre-iPSCs, three replicates. h, Alkaline phosphatase staining on D12. Reprogramming
counts are shown as mean +/-SEM. qPCR quantifications are shown as mean of three technical replicates +/- SD, normalised to GAPDH
transcript levels.
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Figure 3. Zmym2 knockout enhances Nanog-mediated reprogramming in epiblast stem cells (EpiSCs) and somatic cells. a,Western blot
analysis of starting populations of EpiSCs. Both alleles of Zmym2 were disrupted with the CRISPR/Cas9 system. Nanog, Zmym2 or both were
stably overexpressed. b, Average GFP+ colony count of reprogrammed EpiSCs on D12 for Zmym2-/- and WT EpiSCs, per 50,000 cells plated,
three replicates. c, Gene expression analysis of the resulting iPSCs shows them to be faithfully reprogrammed, in contrast to the starting
population of EpiSCs. d, Western blot analysis of starting populations of NSCs. Both alleles of Zmym2 were disrupted with the CRISPR/Cas9
system. Nanog, Zmym2 or both were stably overexpressed. Clustal Omega multiple sequence alignment of KO clones with the WT sequence
and reverse complement sequencing traces of Zmym2KO EpiSCs and NSCs. e, Average iPSC colony count after reprogramming of Zmym2-/and WT NSCs per 75,000 cells plated. f, Fluorescence and brightfield images of iPSCs generated from Zmym2-/- and WT NSCs after retroviral
Oct4, Klf4 and cMyc overexpression and exposure to 2i Plus LIF. Scale bar 500μm. g, Gene expression analysis of the resulting WT and
Zmym2-/- iPSCs by qPCR. h, NSCs were stably transfected with Nanog, Zmym2 or both and reprogrammed with retroviral Oct4, Klf4 and cMyc
in 2i Plus LIF. Average colony count for Zmym2-/- and WT NSCs per 75,000 cells plated, three replicates. Reprogramming counts are shown as
mean +/- SEM. qPCR quantifications are shown as mean of three technical replicates +/- SD, normalised to Gapdh transcript levels.
Page 9 of 18

Wellcome Open Research 2019, 4:88 Last updated: 02 AUG 2019

Figure 4. Zmym2 inhibits embryonic stem cell (ESC) self-renewal. a, Western blot analysis of ESCs stably overexpressing Zmym2 or a
corresponding EV transgene. b, Brightfield images of alkaline phosphatase stained plates of EV- of Zmym2-overexpressing ESCs after 6 days
in medium containing either serum or Serum+LIF. Scale bar 500μm. c, Scores of undifferentiated colonies on D6 after plating in Serum or
Serum Plus LIF. Mean of 3 replicates +/-SEM. d, Zmym2 was disrupted using CRISPR/Cas9. Clones were stably transfected with Zmym2 or a
corresponding EV transgene. Western blot of two resulting ESC clones; the knockout clone was sequenced and used for further experiments.
e, Scores of undifferentiated colonies on D6 after plating WT, Zmym2-/- and Zmym2 rescued lines in Serum or Serum Plus LIF indicate that
Zmym2 deletion may impede differentiation in the absence of LIF. Mean of 3 replicates +/- SEM.
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Figure 5. Zmym2 overexpression correlates with the mis-expression of early lineage markers. a,Brightfield images of Cas9-generated
Zmym2-/- (Figure 4D), WT and Zmym2 overexpressing embryonic stem cells (ESC) in Serum Plus LIF-containing medium. b, Western blot
analysis of these ESC lines. c, RNA Seq analysis was performed on the lines shows an upregulation in the transcript levels of early lineage
specifiers of trophectoderm (TE), ectoderm and EpiSCs (EpiSCs/Ecto), mesoderm (meso) and endoderm (endo) and a corresponding
decrease in the transcript levels of inner cell mass (ICM) markers in Zmym2 overexpressing ESCs. Conversely, Zmym2-/- ESCs have lower
transcript levels of early lineage markers.

Serum Plus LIF-containing medium. Zmym2 overexpressing
cells had higher transcript levels of many lineage specifiers
than control cells including early ectodermal, mesodermal and
endodermal markers, as well as trophectodermal markers, after
normalisation to housekeeping genes. In addition, they had
reduced transcript levels of a number of pluripotency-associated
genes. Conversely, Zmym2KO cells had reduced expression of
differentiation markers. In conclusion, Zmym2 inhibits reprogramming and promotes differentiation. It has a global
effect on the transcriptome of ESCs, increasing the transcription
of differentiation-associated genes and reducing pluripotencyassociated transcripts.

differentiation-promoting factors25. Future work could examine
whether the absence of Zmym2 impacts mouse development
and elucidate its role in vivo.
In conclusion, this work has elucidated the key role of Zmym2
as a barrier to reprogramming and a differentiation-promoting
transcription factor. This is particularly interesting as many previous studies of Nanog’s mechanism of action have identified
positive regulators of its activity11,13. We have shown both more
effective reprogramming and less differentiation upon removal
of Zmym2 demonstrating how the tight control of NANOG by
its binding partners exerts a directive influence on cell identity
transitions, both entering and exiting the pluripotent state.

Discussion
In this work, we show that Zmym2 represents a significant
barrier to Nanog-mediated reprogramming. We observed consistent results using gain and loss of function assays in many
different reprogramming systems, including EpiSCs, fibroblasts and neural stem cells. This corroborates results obtained by
other groups working on RNAi in human cell reprogramming26.
Therefore, ZMYM2 may play a similar role in the control of
NANOG in mouse and human.
We also observe that Zmym2 promotes embryonic stem cell
differentiation. This has also been reported in a Cas9 screen for

Data availability
Underlying data
RNASeq data from WT, Zmym2 knockout- and Zmym2
overexpressing- E14tg2a mouse embryonic stem cells, Accession
number GSE130317: http://identifiers.org/geo:GSE130317
Open Science Framework: ZMYM2. https://doi.org/10.17605/OSF.
IO/TFKHR27
This project contains the following underlying data:
• 1c.pdf (x-ray films for Western blot in Figure 1c)
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• 1g.jpg (x-ray films for Western blot in Figure 1g)

• 4d_1.pdf (x-ray films for Western blot in Figure 4d)

• 2 h.jpg (alkaline phosphatase staining for colony counts
in Figure 2h)

• 5 a KO ESCs.jpg (Brightfield image of KO ESCs shown
in 5a)

• 3 a d 5b.pdf (x-ray films for Western blot in Figure 3a, 3d
and Figure 5b)

• 5 a WT ESCs.jpg (Brightfield image of WT ESCs shown in
5a)

• 3 f_1.tif (Image taken at 488nm of Oct4-GFP+ colonies
for Figure 3f)

• 5 a Zfp198BSD E14.jpg (Brightfield image of OE ESCs
shown in 5a)

• 3 f_2.tif (Brightfield
shown in 3f-1)

• A
 ll data Zmym2 Lawrence.xlsx (All GFP+ colony
counts, Coomassie colony counts, alkaline phosphatase+
colony counts, and qPCR Ct values underlying this paper)

image

of

Oct4-GFP+

colonies

• 3 f_3.tif (Image taken at 488nm of Oct4-GFP+ colonies
for Figure 3f)
• 3 f_4.tif (Brightfield
shown in 3f-3)

image

of

Oct4-GFP+

colonies

• 4a.pdf (x-ray films for Western blot in Figure 4a)
• 4 b_1.tif (Brightfield image of alkaline phosphatase-stained
well shown in 4b)

• C
 C0: Results.pdf (PDF confirming that these results
have been declared CC0)
Data are available under the terms of the Creative Commons
Zero “No rights reserved” data waiver (CC0 1.0 Public domain
dedication).

• 4 b_3.tif (Brightfield image of alkaline phosphatase-stained
well shown in 4b)
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RNA Biomedical Institute, Sun Yat-Sen Memorial Hospital, Zhongshan School of Medicine, Sun Yat-Sen
University, Guangzhou, China
This manuscript proves that Zmym2 acts as a repressor in Nanog-mediated reprogramming through gain
and loss of function assays. The novelty of this manuscript is moderate, and there are some problems that
needs to be improved.
Main points:
1. The information in the introduction is too simple and incomplete. There are lots of proteins in
NANOG interactome, please give more detailed reasons why the author chose the ZMYM2 as the
research object. Also, the nature and function of ZMYM2 that has been studied so far could be
introduced.
2. In the section of “Zmym2 reduces ESC self-renewal”, the author said that “Neither KD nor
overexpression lines had any change in Nanog transcript or protein levels”, however, as is shown
in Figure 2e, when Zmym2 is overexpressed, the transcript level of Nanog also increases, which
seems that the expression of Nanog is regulated by Zmym2.
3. In the discussion part, could you please give some possible mechanism about why Zmym2 have a
pronounced positive effect on Nanog-mediated reprogramming but a minimal effect on
reprogramming of no-Nanog-mediated?
4. It seems that the authors were not serious enough when making figures. The detail of this criticism
would be listed in the “minor points” section.
Minor points:
1. It’s a bit confusing to emphasize that NANOG is a “homeodomain-containing” transcription factor in
both the abstract and the first paragraph of the introduction.
2. The method of reprogramming epiblast stem cell is missing.

3. Font size is expected to be 8-10 pt in all figures. For example, the fonts are too large in Figure 4d
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3. Font size is expected to be 8-10 pt in all figures. For example, the fonts are too large in Figure 4d
while the ones are too small in Figure 3.
4. The upper half part of error bar of the “ESCs” is missing in Figure 1d.
5. The meaning of “Pool” should be explained in the figure legend of Figure 1.
6. What dose “Oct4_” mean in Figure 2c and 3g?
7. It’s inaccurate to regard neural stem cells as somatic cells in the title of Figure 3.
8. “Zmym2” is expected to be italic in all figures.
9. In the result of western blot, the “alpha tublin” should be written as “α-TUBLIN”.
10. The P value should be provided in every bar graph.
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Tom Burdon
The Roslin Institute and R(D)VS, University of Edinburgh, Edinburgh, UK
This thorough study investigates a role for Zmym2 in Nanog-mediated reprogramming, and in ESC
differentiation. By using RNA knock-down, gene knock-out and over-expression in a series of bespoke
reprogramming tests, and a standard ESC self-renewal assay, the authors have comprehensively
demonstrated that Zmym2 antagonises Nanog-driven reprogramming and promotes the loss of
pluripotency in ESCs. This novel finding significantly extends the previously reported observation that
Zmym2 physically interacts closely with the Nanog protein in ESCs.
Nanog is a member of a group of ancillary pluripotency-associated factors that are not essential in all
circumstances, and may vary in their importance in embryo stem cells of different species. Given the
significant protein sequence divergence of Nanog outside the core DNA binding domain, future studies
may investigate what regions of Nanog (or partners) interact with Zmym2, and the degree to which this
interaction is conserved in Nanog-expressing cell types, and between species.
However, questions that might be answered using the available data and included directly in this present
report, are:
1. How does Zmym2 expression affect Nanog target gene expression? Analysis of the RNA seq data
for effects on Nanog target expression in the KO, WT and OE cells might shed light on how Zmym2
influences Nanog function.
2. Similarly, does Zmym2 affect self-renewal/differentiation signalling in ESCs? The relevant data
presented in Figure 5 shows striking induction of Cdx2 and Brachyury as well as BMP2. Since
Cdx2 and Brachyury are known targets for Wnt/b-catenin signalling, is there evidence of Zmym2
upregulation of this pathway. Or is their induction mediated via expression of BMP2, and
accompanied by upregulation of other BMP signalling/targets?
Other points for consideration are:
The introduction/discussion would benefit from mentioning background information on Zmym2, as
well as its pattern of expression during early differentiation (upregulation during EpiSC formation?).
Could there be any significance to Zmym2/FGFR association and Nanog function?
Clarification in the first part of the results that the "control" ZFP281 is a Nanog interacting protein.
Minor typo - Figure legend 2 “ 75,000 plates NSCs” - “plated”.
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Andrew Johnson
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I think this is a very good and interesting paper that addresses an important issue in stem cell biology.
Some years ago, NANOG was identified as a “gateway to pluripotency”, so how its activity is regulated
during reprogramming is of considerable interest. Here the authors investigate the activity of a
transcription factor called ZMYM2 that they have identified as a component of the NANOG interactome,
and they show that it inhibits NANOG activity both during reprogramming and self-renewal. Other studies,
including work by the same lab, have demonstrated the augmentation of NANOG activity by components
of the interactome; this is the first to my knowledge to show an inhibitory activity. Interestingly, ZMYM2
does not inhibit NANOG expression, so its effects must be biochemical, and future studies to elucidate
these biochemical activities will also be of considerable interest in the field. The studies are thorough, well
executed and convincing. For example, the authors use several different reprogramming contexts,
including epiSC, fibroblasts and neural stem cells to demonstrate the inhibitory effects of ZMYM2 on
reprogramming. They also use a combination of knockout and overexpression experiments, which clearly
demonstrate complementary results that reinforce the paper’s conclusions. Their data also show that
ZMYM2 inhibits self-renewal by promoting differentiation, suggesting it may play an interesting role in
cell-specification in vivo. In all this paper is certainly worthy of indexing and it will be of interest to the field.
I think a couple of minor issues should be addressed.
First, the second line of the Introduction states that pluripotent cells possess the ability to self-renew.
However, this is only true of pluripotent stem cells maintained in culture. The pluripotent cells in an
embryo do not necessarily self-renew, particularly in non-mammalian systems where the number of
Page 17 of 18

Wellcome Open Research 2019, 4:88 Last updated: 02 AUG 2019

embryo do not necessarily self-renew, particularly in non-mammalian systems where the number of
pluripotent cells increases by cleavage rather than expansion of an epiblast.
In Figure 4d the difference between the mutant and a knockout ESC lines should be made clearer. The
different patterns of ZMYM2 in the two lines should also be explained in the text.
Figure 4e does not show ESC in serum plus LIF.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Developmental biology, stem cell biology.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.

Page 18 of 18

